Novo Returns Once-Monthly GLP-1 Rights to Ascendis as Pipeline Reset Deepens

Novo Nordisk has walked away from its agreement with Danish biotech Ascendis Pharma to develop a once-monthly GLP-1 obesity injection, returning full rights to the program in a move that deepens the strategic reset now underway at the rebranded company.

What Happened

Days after announcing it would operate day-to-day as simply 'Novo,' the drugmaker confirmed it is exiting the roughly $285 million pact signed with Ascendis in late 2024. The deal had licensed Ascendis's TransCon technology to build a long-acting, once-monthly formulation of semaglutide — the active molecule behind Ozempic and Wegovy.

Rights to the obesity and metabolic assets revert to Ascendis, which says it plans to advance the once-monthly program itself. Industry reporting notes this is the second monthly-injection GLP-1 program Novo has exited this year, a sign that management is concentrating resources on its oral weight-loss pill and next-generation candidates as Eli Lilly chips away at Novo's obesity market lead.

Who Is Affected

• Obesity patients hoping for less-frequent dosing options, whose timeline just lengthened
• Ascendis Pharma, which regains the assets but must now fund development alone
• Investors and analysts recalibrating both pipelines ahead of Novo's strategy day
• Gray-market observers: with no once-monthly GLP-1 approved anywhere, any seller claiming to offer 'monthly semaglutide' today is by definition offering an unapproved product

Timeline

• November 2024: Novo and Ascendis sign the licensing pact worth roughly $285 million in upfront and near-term value
• 2025–2026: Lilly's oral weight-loss pill reaches patients and begins eroding Novo's share of new prescriptions
• September 15, 2026: Exit confirmed; rights revert to Ascendis; the rebrand to 'Novo' is announced in the same window
• Late September 2026: Strategy day where management is expected to detail pipeline priorities

What This Means for Researchers

The consolidation confirms that ultra-long-acting GLP-1 delivery remains investigational. No once-monthly GLP-1 receptor agonist has cleared any major regulator, so claims of 'monthly GLP-1' products in the research-chemical or gray market should be treated as mislabeled at best. The underlying science — extending semaglutide's half-life through prodrug technology — remains sound, and Ascendis's stated intent to continue development keeps the frontier active for labs studying long-acting incretin analogs.

How to Verify Your Peptides

Whether you work with semaglutide or any other peptide, identity and purity claims deserve independent confirmation. Our guides to how peptide testing works and HPLC versus LC-MS analysis explain what a legitimate certificate of analysis must contain. For semaglutide specifically, see our semaglutide testing and purity guide.

Safe Alternatives

Clinically approved GLP-1 therapies remain available through legitimate channels, and well-characterized research compounds are documented in our peptide profiles. Our vendor directory lists suppliers that publish third-party testing records, so you can avoid the mislabeled and unapproved products that pipeline news tends to precede.

Sources

Industry reports and regulatory announcements, September 2026.